[go: up one dir, main page]

PL3558339T3 - Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania - Google Patents

Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania

Info

Publication number
PL3558339T3
PL3558339T3 PL17884258.9T PL17884258T PL3558339T3 PL 3558339 T3 PL3558339 T3 PL 3558339T3 PL 17884258 T PL17884258 T PL 17884258T PL 3558339 T3 PL3558339 T3 PL 3558339T3
Authority
PL
Poland
Prior art keywords
multimeralic
methods
cell modulating
modulating polypeptides
polypeptides
Prior art date
Application number
PL17884258.9T
Other languages
English (en)
Inventor
Iii Ronald D. Seidel
Rodolfo CHAPARRO
Original Assignee
Cue Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cue Biopharma, Inc. filed Critical Cue Biopharma, Inc.
Publication of PL3558339T3 publication Critical patent/PL3558339T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
PL17884258.9T 2016-12-22 2017-12-20 Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania PL3558339T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438272P 2016-12-22 2016-12-22
US201762470774P 2017-03-13 2017-03-13
US201762555435P 2017-09-07 2017-09-07
US201762582132P 2017-11-06 2017-11-06
PCT/US2017/067663 WO2018119114A1 (en) 2016-12-22 2017-12-20 T-cell modulatory multimeric polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
PL3558339T3 true PL3558339T3 (pl) 2024-08-05

Family

ID=62627190

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17884258.9T PL3558339T3 (pl) 2016-12-22 2017-12-20 Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania

Country Status (19)

Country Link
US (20) US20190352363A1 (pl)
EP (2) EP3558339B1 (pl)
JP (4) JP7250677B2 (pl)
KR (1) KR102760578B1 (pl)
CN (6) CN116970060A (pl)
AU (1) AU2017379900B2 (pl)
BR (1) BR112019012964A2 (pl)
CA (1) CA3043630A1 (pl)
DK (1) DK3558339T5 (pl)
ES (1) ES2973548T3 (pl)
IL (4) IL297617B2 (pl)
MX (2) MX2019007611A (pl)
MY (1) MY202029A (pl)
PH (1) PH12019501413A1 (pl)
PL (1) PL3558339T3 (pl)
PT (1) PT3558339T (pl)
SI (1) SI3558339T1 (pl)
TW (2) TWI852752B (pl)
WO (1) WO2018119114A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475628A (zh) 2016-05-18 2019-03-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
AU2017379900B2 (en) 2016-12-22 2024-12-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
WO2019051127A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
BR112021011838A2 (pt) * 2018-12-19 2021-08-31 Cue Biopharma, Inc. Peptídeos multiméricos moduladores de células t e métodos de uso destes
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP3935080A4 (en) * 2019-03-06 2023-04-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. MADCAM TARGETED IMMUNOTLERANCE
CN118852456A (zh) * 2019-05-29 2024-10-29 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
EP3986448A4 (en) * 2019-06-19 2023-07-12 Cue Biopharma, Inc. MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
EP4030897A4 (en) * 2019-09-20 2023-10-18 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
AU2020369573A1 (en) * 2019-10-23 2022-03-24 Cue Biopharma, Inc. Modified cytotoxic T cells and methods of use thereof
JP2023500574A (ja) * 2019-10-23 2023-01-10 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節性キメラ分子及びその使用方法
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
US20210188934A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
WO2021140416A2 (en) 2020-01-10 2021-07-15 Bright Peak Therapeutics Ag Modified il-2 polypeptides and uses thereof
US11491205B2 (en) * 2020-01-14 2022-11-08 Synthekine, Inc. Biased IL2 muteins methods and compositions
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
WO2021195108A1 (en) * 2020-03-24 2021-09-30 Cue Biopharma, Inc. T cell modulatory polypeptides and methods of use thereof
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
EP4149534A4 (en) 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
AR122863A1 (es) * 2020-07-02 2022-10-12 Inhibrx Inc Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos
CN113912735B (zh) * 2020-07-08 2025-03-28 南京师范大学 多肽二聚体及其用途
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
IL302276A (en) 2020-10-23 2023-06-01 Asher Biotherapeutics Inc Fusions with cd8 antigen binding molecules for modulating immune cell function
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents
EP4340866A4 (en) 2021-05-19 2025-05-21 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
KR20240041379A (ko) 2021-07-09 2024-03-29 브라이트 피크 테라퓨틱스 아게 Il-2에 접합된 체크포인트 억제제 및 이의 용도
CA3222359A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Conjugates of checkpoint inhibitors with il-2, and uses thereof
WO2023046156A1 (en) * 2021-09-26 2023-03-30 Wuxi Biologics (Shanghai) Co. Ltd. Il-2 variants and fusion proteins thereof
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
CN116036243A (zh) * 2022-04-20 2023-05-02 北京大学宁波海洋药物研究院 受体偏向的peg化il-2变体组合及其应用
KR20250039519A (ko) 2022-06-16 2025-03-20 세파론 엘엘씨 항-pd-1 항체-약화된 il-2 면역접합체 및 그의 용도
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2025059162A1 (en) * 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH06510799A (ja) 1992-06-25 1994-12-01 シティ・オブ・ホープ サイトメガロウイルスのポリペプチドによる細胞溶解性ｔ−リンパ球の誘導
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
GB9307371D0 (en) 1993-04-08 1993-06-02 Walls Alan J Fusion proteins
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
CA2196085C (en) 1994-07-29 2002-12-10 Hing C. Wong Mhc complexes and uses thereof
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US6218363B1 (en) 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
ATE321855T1 (de) 1997-01-14 2006-04-15 Human Genome Sciences Inc Tumor-nekrose-faktor rezeptor 5
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
JP3816959B2 (ja) 1997-02-13 2006-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 肝細胞癌の予防および処置
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
WO1998050527A1 (en) 1997-05-08 1998-11-12 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
US20030007978A1 (en) 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6696304B1 (en) 1999-02-24 2004-02-24 Luminex Corporation Particulate solid phase immobilized protein quantitation
US6960652B2 (en) 1999-03-30 2005-11-01 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
US7446189B1 (en) 1999-04-30 2008-11-04 Institut De Recherches Cliniques De Montreal Nucleic acids encoding mutant human CD80 and compositions comprising the same
US20020006664A1 (en) 1999-09-17 2002-01-17 Sabatini David M. Arrayed transfection method and uses related thereto
HUP0203968A3 (en) * 2000-01-14 2004-09-28 Corixa Corp Seattle Compositions and methods for the therapy and diagnosis of prostate cancer
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
WO2001090747A2 (en) 2000-05-25 2001-11-29 Sunol Molecular Corporation Modulation of t-cell receptor interactions
US20020122820A1 (en) 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6800748B2 (en) 2001-01-25 2004-10-05 Large Scale Biology Corporation Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector
CA2440773A1 (en) 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules
US6811785B2 (en) 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
AU2002309865A1 (en) 2001-05-15 2002-11-25 University Of Medicine & Dentistry Of New Jersey Methods for analyzing interactions between proteins in live and intact cells
CN1533432A (zh) 2001-06-04 2004-09-29 MLʵ���ҹ������޹�˾ 高水平、大规模生产重组蛋白的组合体和方法
US20030017134A1 (en) 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
AU2002368044A1 (en) 2001-06-22 2004-04-19 Maxygen, Inc. Co-stimulatory molecules
WO2003006632A2 (en) 2001-07-12 2003-01-23 Canvac Methods and compisitions for activation human t cells in vitro
WO2003040307A2 (en) 2001-07-27 2003-05-15 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
AU2002366433A1 (en) 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US6911321B2 (en) 2001-12-19 2005-06-28 Genentech, Inc. Non-human primate Fc receptors and methods of use
CN100343393C (zh) 2002-03-15 2007-10-17 布赖汉姆妇女医院 适合治疗剂全身性递送的中央气道给药
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
US7611700B2 (en) 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
US20070148162A1 (en) 2003-02-27 2007-06-28 Ranjit Bhardwaj Molecule which binds cd80 and cd86
AU2003901876A0 (en) 2003-04-17 2003-05-08 The Macfarlane Burnet Institute For Medical Research And Public Health Viral vector
US20050042641A1 (en) 2003-05-27 2005-02-24 Cold Spring Harbor Laboratory In vivo high throughput selection of RNAi probes
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
EP2783699A1 (en) 2003-09-05 2014-10-01 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
US7470513B2 (en) 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
AU2005227263A1 (en) 2004-03-05 2005-10-06 Novartis Vaccines And Diagnostics, Inc. In vitro test system for predicting patient tolerability of therapeutic agents
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR20070107687A (ko) 2004-12-31 2007-11-07 제넨테크, 인크. Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
KR20080082628A (ko) 2005-11-10 2008-09-11 리셉터 바이오로직스 인크 수용체 및 리간드 이소형태의 제조 방법
US7943133B2 (en) 2006-02-02 2011-05-17 Boston Biocom Llc Mesothelin antibody protein fusions and methods of use
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
ES2549128T3 (es) 2006-05-19 2015-10-23 Technion Research And Development Foundation Ltd. Proteínas de fusión, usos de las mismas y procesos para producir las mismas
EP1889851A1 (en) 2006-08-18 2008-02-20 Charite Universitätsmedizin-Berlin PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
US8992937B2 (en) 2006-08-28 2015-03-31 Washington University Disulfide trap MHC class I molecules and uses therefor
CN101573448B (zh) 2006-12-28 2012-07-11 株式会社癌免疫研究所 Hla-a*1101限制的wt1肽及含有其的药物组合物
EP2129389B1 (en) 2007-02-15 2014-10-08 MannKind Corporation A method for enhancing t cell response
WO2008113970A2 (en) 2007-03-16 2008-09-25 Ucl Business Plc Peptides
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP2615172A1 (en) 2007-04-27 2013-07-17 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
US8926961B2 (en) 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
CN101418309B (zh) 2007-10-23 2011-05-04 中国农业科学院上海兽医研究所 柔嫩艾美耳球虫蛋白质二硫键异构酶基因的克隆、表达及应用
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
DK2172211T3 (en) * 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
EP2184070A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US20120178703A1 (en) 2009-06-25 2012-07-12 Commisariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
US9695410B2 (en) 2010-07-15 2017-07-04 Technion Research & Development Foundation Limited Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides
CN105017429B (zh) 2010-09-21 2021-04-06 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
LT3075745T (lt) * 2011-02-10 2018-11-26 Roche Glycart Ag Mutavę interleukino-2 polipeptidai
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
TWI582112B (zh) 2011-04-21 2017-05-11 西雅圖遺傳學公司 新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（二）
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2667864T3 (es) 2011-06-22 2018-05-14 F. Hoffmann-La Roche Ag Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I
EP2726101B1 (en) 2011-06-30 2018-08-08 Genzyme Corporation Inhibitors of t-cell activation
WO2013030620A2 (de) 2011-08-30 2013-03-07 Jacobs University Bremen Ggmbh Gen codiert für ein mhc-klasse-i-molekül, plasmid, expressionssystem protein, multimer, reagenz und kit zum analysieren einer t-zellen-frequenz
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
WO2013116656A1 (en) 2012-02-03 2013-08-08 Emory University Immunostimulatory compositions, particles, and uses related thereto
RU2015106812A (ru) * 2012-08-02 2016-09-27 Ф.Хоффманн-Ля Рош Аг Способ получения мономерных и мультимерных молекул и их применение
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
BR112015011111A2 (pt) 2012-11-30 2017-11-14 Roche Glycart Ag proteína multifuncional e formulação farmacêutica
CN105121715B (zh) 2012-12-11 2018-10-26 艾伯特叶史瓦大学爱因斯坦医学院 高通量受体:配体鉴定方法
RU2015129640A (ru) * 2012-12-21 2017-01-26 Ф.Хоффманн-Ля Рош Аг Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
EP3587448B1 (en) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
HK1220376A1 (zh) 2013-03-15 2017-05-05 Angelica Therapeutics, Inc. 修饰的毒素
WO2014157692A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
CN111781359A (zh) 2013-05-13 2020-10-16 株式会社癌免疫研究所 用于预测免疫疗法的临床效果的方法
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
BR112016001114B1 (pt) 2013-07-19 2023-02-14 Vib Vzw Composição compreendendo uma proteína de fusão e uso da referida composição
KR20250152665A (ko) * 2013-07-31 2025-10-23 암젠 인크 Ｆc-함유 폴리펩타이드의 안정화
SG11201605632SA (en) 2014-01-21 2016-08-30 Einstein Coll Med Cellular platform for rapid and comprehensive t-cell immunomonitoring
US20160152725A1 (en) 2014-02-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
EP3112378B1 (en) 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
SG10202006338UA (en) 2014-06-18 2020-08-28 Albert Einstein College Medicine Inc Syntac polypeptides and uses thereof
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
DK3172227T3 (da) 2014-07-21 2019-12-02 Delinia Inc Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
AU2015301753B2 (en) 2014-08-12 2021-04-08 Massachusetts Institute Of Technology Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
AU2015308527C1 (en) 2014-08-29 2021-07-15 F. Hoffmann-La Roche Ag Combination therapy of tumor-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
PE20170912A1 (es) 2014-11-14 2017-07-12 Novartis Ag Conjugados de anticuerpo-farmaco
PL3223850T3 (pl) 2014-11-26 2020-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Receptory limfocytów t przeciwko zmutowanemu kras
CN107531805A (zh) 2015-03-05 2018-01-02 弗雷德哈钦森癌症研究中心 免疫调节融合蛋白及其用途
EP3286222A4 (en) 2015-03-23 2018-08-08 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
EP3299028B1 (en) 2015-05-20 2024-10-30 Sumitomo Pharma Co., Ltd. Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
US11046745B2 (en) 2015-07-14 2021-06-29 BioNTech SE Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof
US20180221503A1 (en) 2015-07-31 2018-08-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
CN106565836B (zh) 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
CN116327902A (zh) 2015-11-20 2023-06-27 纪念斯隆凯特林癌症中心 用于治疗癌症的方法和组合物
US20190365656A1 (en) 2016-01-04 2019-12-05 Cour Pharmaceuticals Development Company, Inc. Particles encapsulating fusion proteins containing linked epitopes
SG10202007639SA (en) 2016-01-11 2020-09-29 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cell systems for immune indications
CA3012037A1 (en) 2016-01-27 2017-08-03 Csl Behring Recombinant Facility Ag Recombinant igg fc multimers
EP3423108A4 (en) 2016-03-02 2019-10-02 Cue Biopharma, Inc. T CELL MODULATING MULTIPLE POLYPEPTIDES AND METHOD OF USE THEREOF
CA3014466A1 (en) * 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN109219445B (zh) 2016-04-01 2022-08-26 上海煦顼技术有限公司 嵌合抗原受体修饰细胞治疗癌症的应用
KR20240115933A (ko) 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CA3022331A1 (en) 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
CN109475628A (zh) 2016-05-18 2019-03-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
KR102501827B1 (ko) 2016-09-16 2023-02-22 베이롤 칼리지 오브 메드신 바이러스-특이적인 t-세포의 활성화 및 확장을 위한 플랫폼
EP3538559B1 (en) 2016-11-09 2025-04-09 UTI Limited Partnership Recombinant pmhc class ii molecules
AU2017379900B2 (en) 2016-12-22 2024-12-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3049244A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
EP3595706A1 (en) 2017-03-17 2020-01-22 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
WO2019005886A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS
EP3446702A1 (en) 2017-08-23 2019-02-27 Medizinische Hochschule Hannover Synthetic vaccine
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
IL297361B2 (en) * 2017-09-07 2024-07-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2019051126A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
JP2021500855A (ja) 2017-09-07 2021-01-14 キュー バイオファーマ， インコーポレイテッド 抗原提示ポリペプチドおよびその使用方法
WO2019070541A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. HPV-SPECIFIC BINDING MOLECULES
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP3755711A4 (en) 2018-02-20 2021-11-24 Technion Research & Development Foundation Limited IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER
MX2021003938A (es) 2018-10-05 2021-08-11 Int Inst Cancer Immunology Inc Composicion para prevenir o tratar un tumor benigno.
TWI856047B (zh) 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020132368A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020132365A2 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
BR112021011838A2 (pt) 2018-12-19 2021-08-31 Cue Biopharma, Inc. Peptídeos multiméricos moduladores de células t e métodos de uso destes
WO2020132366A2 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020132135A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020132136A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP3935079A4 (en) 2019-03-06 2023-03-22 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR ANTIGEN PRESENTING POLYPEPTIDES AND METHODS OF USE THEREOF
EP3935080A4 (en) 2019-03-06 2023-04-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP7668226B2 (ja) 2019-03-30 2025-04-24 ビオンテック ユーエス インコーポレイテッド Ｔ細胞組成物を調製するための組成物および方法、ならびにそれらの使用
CN118852456A (zh) 2019-05-29 2024-10-29 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
AU2020287373A1 (en) 2019-06-05 2022-01-06 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
EP3986448A4 (en) 2019-06-19 2023-07-12 Cue Biopharma, Inc. MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
EP4030897A4 (en) 2019-09-20 2023-10-18 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
AU2020369573A1 (en) 2019-10-23 2022-03-24 Cue Biopharma, Inc. Modified cytotoxic T cells and methods of use thereof
JP2023500574A (ja) 2019-10-23 2023-01-10 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節性キメラ分子及びその使用方法
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
US20210188934A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
KR20220147107A (ko) 2020-02-28 2022-11-02 도쿠리츠다이가쿠호징 가나자와다이가쿠 면역 제어법, 면역 제어용 핵산 조성물 및 그의 용도
WO2021195411A1 (en) 2020-03-25 2021-09-30 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
GB202005617D0 (en) 2020-04-17 2020-06-03 Adaptimmune Ltd Improved t cell manufacturing process
TW202200188A (zh) 2020-05-12 2022-01-01 日商大日本住友製藥股份有限公司 用以處置癌症之醫藥組合物
EP4149534A4 (en) 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
CN113823723A (zh) * 2020-06-18 2021-12-21 光宝光电(常州)有限公司 发光二极管封装结构
WO2022015880A2 (en) 2020-07-14 2022-01-20 Cue Biopharma, Inc. T-cell modulatory polypeptides with conjugation sites and methods of use thereof
IL302276A (en) 2020-10-23 2023-06-01 Asher Biotherapeutics Inc Fusions with cd8 antigen binding molecules for modulating immune cell function
WO2022099156A2 (en) 2020-11-06 2022-05-12 Cue Biopharma, Inc. T-cell modulatory polypeptides with conjugation sites and methods of use thereof
WO2022119958A1 (en) 2020-12-02 2022-06-09 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2022125711A1 (en) 2020-12-09 2022-06-16 Asher Biotherapeutics, Inc. Targeted cytokine construct for engineered cell therapy
WO2022125694A1 (en) 2020-12-09 2022-06-16 Asher Biotherapeutics, Inc. Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
WO2022197971A1 (en) 2021-03-19 2022-09-22 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
WO2022226058A1 (en) 2021-04-22 2022-10-27 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
EP4426721A4 (en) 2021-11-04 2025-10-08 Cue Biopharma Inc MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
JP2024541334A (ja) 2021-11-24 2024-11-08 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチドおよびその使用方法
WO2023137156A2 (en) 2022-01-13 2023-07-20 Cue Biopharma, Inc. T cell modulatory polypeptides with conjugation sites and methods of use thereof

Also Published As

Publication number Publication date
CN110325205B (zh) 2023-08-15
US20220033456A1 (en) 2022-02-03
IL303806A (en) 2023-08-01
US20190352363A1 (en) 2019-11-21
IL266696B (en) 2022-12-01
JP7560641B2 (ja) 2024-10-02
TW202400216A (zh) 2024-01-01
US20230257439A1 (en) 2023-08-17
TW201829451A (zh) 2018-08-16
IL308851B1 (en) 2025-03-01
US20230220032A1 (en) 2023-07-13
US20240076344A1 (en) 2024-03-07
EP4360647A2 (en) 2024-05-01
KR20190111022A (ko) 2019-10-01
US20220177536A1 (en) 2022-06-09
JP7403703B2 (ja) 2023-12-22
AU2017379900B2 (en) 2024-12-05
SI3558339T1 (sl) 2024-05-31
JP2023113888A (ja) 2023-08-16
US11117945B2 (en) 2021-09-14
PH12019501413A1 (en) 2020-03-16
US20220064247A1 (en) 2022-03-03
US11708400B2 (en) 2023-07-25
US20250243253A1 (en) 2025-07-31
US12421287B2 (en) 2025-09-23
CN116970060A (zh) 2023-10-31
US20250092110A1 (en) 2025-03-20
CA3043630A1 (en) 2018-06-28
IL297617B2 (en) 2023-11-01
US20210107962A1 (en) 2021-04-15
IL297617A (en) 2022-12-01
US20220356224A1 (en) 2022-11-10
US20230399372A1 (en) 2023-12-14
IL266696B2 (en) 2023-04-01
JP7250677B2 (ja) 2023-04-03
IL308851A (en) 2024-01-01
US11401314B2 (en) 2022-08-02
US20240083964A1 (en) 2024-03-14
EP4360647A3 (en) 2024-07-24
EP3558339A1 (en) 2019-10-30
US11530248B2 (en) 2022-12-20
JP2023027295A (ja) 2023-03-01
US11370821B2 (en) 2022-06-28
US10927158B2 (en) 2021-02-23
CN117024560A (zh) 2023-11-10
CN117903282A (zh) 2024-04-19
US11987610B2 (en) 2024-05-21
US11905320B2 (en) 2024-02-20
IL303806B1 (en) 2024-01-01
CN116970061A (zh) 2023-10-31
MX2023013883A (es) 2023-12-11
TWI869327B (zh) 2025-01-11
BR112019012964A2 (pt) 2019-10-08
ES2973548T3 (es) 2024-06-20
DK3558339T3 (da) 2024-02-26
US11851467B2 (en) 2023-12-26
KR102760578B1 (ko) 2025-02-03
US12180258B2 (en) 2024-12-31
WO2018119114A1 (en) 2018-06-28
MY202029A (en) 2024-03-29
EP3558339B1 (en) 2024-01-24
DK3558339T5 (da) 2024-09-02
PT3558339T (pt) 2024-03-15
JP7295325B2 (ja) 2023-06-20
US20240199715A1 (en) 2024-06-20
EP3558339A4 (en) 2020-08-19
IL308851B2 (en) 2025-07-01
US20200199181A1 (en) 2020-06-25
IL266696A (en) 2019-07-31
AU2017379900A1 (en) 2019-06-13
IL297617B1 (en) 2023-07-01
US11377478B2 (en) 2022-07-05
JP2024037852A (ja) 2024-03-19
US12152061B2 (en) 2024-11-26
CN110325205A (zh) 2019-10-11
US12145973B2 (en) 2024-11-19
IL303806B2 (en) 2024-05-01
TWI852752B (zh) 2024-08-11
US11739133B2 (en) 2023-08-29
US20220289808A1 (en) 2022-09-15
US20240141006A1 (en) 2024-05-02
US20210198337A1 (en) 2021-07-01
MX2019007611A (es) 2020-07-29
CN116970059A (zh) 2023-10-31
US20200207824A1 (en) 2020-07-02
US11505588B2 (en) 2022-11-22
JP2020511949A (ja) 2020-04-23
US20220340632A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
PL3558339T3 (pl) Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania
IL271025A (en) Multibiotic agents and methods of using the same
IL272085A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
DK3436048T3 (da) Neoantigener og fremgangsmåder til anvendelse deraf
IL282372A (en) Haploid induction compositions and methods for use therefor
DK3601358T5 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3534899T3 (da) Forbindelser og fremgangsmåder til modulering af interleukin-2-inducerbar t-cellekinase
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3356404T3 (da) Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3551660T5 (da) Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3436030T3 (da) Kimæriske receptorer og fremgangsmåder til anvendelse deraf
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3230319T3 (da) Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
DK3249777T3 (da) Adapter og fremgangsmåde til opladningskontrol
DK3464282T3 (da) Heteroarylsubstituerede pyridiner og fremgangsmåder til anvendelse
DK3148579T3 (da) Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
DK3221357T3 (da) Fælles letkæder og fremgangsmåder til anvendelse
DK3653221T5 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
PL3551664T3 (pl) Przeciwciała i polipeptydy skierowane przeciwko cd127
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3668512T3 (da) Pyruvatkinasemodulatorer og anvendelse deraf
PL3157552T3 (pl) Polipeptydy syntac i ich zastosowania